Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Gothenburg, February 9, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announced that the company has received approval from the Swedish Medical Products Agency to start the clinical phase I/II study CARMA in patients with B-cell lymphoma that no longer respond to standard treatment or have relapsed.CARMA is a single-arm, unblinded, multicenter study that aims to evaluate the safety profile and treatment effect after one dose of ELC-301. It

BioStock: 2023 springboard for Spago’s radionuclide cancer therapy

In 2023, Swedish biotech Spago Nanomedical kicked off its journey in the clinic with radionuclide cancer therapy Tumorad. Ending the year with the first patient dosed in the phase I trial and a SEK 30.6 million capital raise, Spago has strong momentum going into 2024. BioStock spoke with Spago’s CEO Mats Hansen to hear about the progress made in 2023 and what he is most looking forward to this year.Read the interview with Mats Hansen at biostock.se: 2023 springboard for Spago’s radionuclide cancer therapy - BioStock 

Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market

Prostatype Genomics AB ("Prostatype Genomics" or "the Company") announces that its wholly-owned US subsidiary Prostatype Genomics, Inc. has been accredited by the CAP (College of American Pathologists) Laboratory Accreditation Program. The Company has thus achieved three major regulatory milestones in February 2024 towards entering the US market: a signed CLIA laboratory agreement with its lab partner ResearchDx, acquisition of a CLIA Certificate, and now CAP laboratory accreditation. The final regulatory step needed before being able to enter the US prostate cancer market is a formal

Minesto reaches historic milestone – first electricity to grid with tidal powerplant Dragon 12 (1.2 MW)

Minesto, leading ocean energy developer, today announces that a key milestone has been reached: The utility-scale tidal powerplant Dragon 12 - rated at 1.2 MW - has been successfully commissioned and, in the early morning of February 9, delivered its first electricity to the national grid in the Faroe Islands.The Dragon 12 is Minesto’s first tidal energy kite in megawatt-scale. It has now been successfully commissioned and has generated electricity at satisfactory levels in its first phase of operation. The 12-meter wide and 28-ton heavy subsea kite, anchored with a tether to the seabed, is

New roof for 16 apartment buildings in Ukraine with roofing products donated by SSAB & Ruukki

Humanitarian reconstruction work in Ukraine, coordinated by the Swedish charity organization OperationAid, has progressed to repair houses damaged by Russian aggression. In January 2024, sixteen apartment buildings in the Mykolaiv region were renovated with roofing materials donated by SSAB and Ruukki. The war in Ukraine continues with devastating effects. To help people in need, we donated approximately 2,500 square meters of roofing materials for the reconstruction in December 2023. The products were manufactured from SSAB's steel at the Ruukki plant near Kiev. “Sixteen multi-

Invitation to web presentation of Formpipe’s Q4 report 2023.

Formpipe will publish its interim report for the forth quarter 2023 on Friday 16 February 2024 at 08:15 (CET).The same day at 11:00 (CET), Formpipe’s President and CEO Magnus Svenningson will host a web presentation in English which is webcasted live on: http://www.formpipe.com/en/q42023, where it also will be available on demand shortly afterwards. Following the presentation, Magnus Svenningson, and Joakim Alfredson CFO, will be available to answer questions. The report and presentation will be available at: www.formpipe.com/en/investors/reports-and-presentations Welcome!

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseFebruary 9, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On February 8, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |3,497 |4.0139

Brain+ partners with Quiddity Health, the #1 UK digital healthcare market specialist, to prepare UK market entry for CST-Therapist Companion

·Quiddity Health has a strong track-record of helping innovative digital therapeutic companies successfully enter the UK healthcare market and reach commercial scale    ·Brain+ plans to have a UK version 2.0 of CST-Therapist Companion, its new digital solution to support effective dementia therapy, ready for UK market release in Q3 2024  ·Initially, Quiddity Health will work with Brain+ to develop a targeted go-to-market plan for CST-Therapist Companion in the UK and build relevant pre-sale customer engagements   ·Post market release, Quiddity Health will act as Brain+’

Year-end Report 1 January – 31 December 2023

· Continued stable growth despite restructuring of commercial organization, and satisfactory start in the US with significant opportunities ahead · Restructuring program completed with planned cost reduction expected 2024 · 510(k)-process ongoing with US FDA for big toe implant“Despite significantly restructuring our sales force, we ended the year with another record quarter. On average, we have grown our gross order intake by more than 50% during the last five quarters. During 2023, the gross order intake reached SEK 11.1m (+56%). The usage of our technology increased globally and

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Gothenburg, February 9, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announced that the company has received approval from the Swedish Medical Products Agency to start the clinical phase I/II study CARMA in patients with B-cell lymphoma that no longer respond to standard treatment or have relapsed.CARMA is a single-arm, unblinded, multicenter study that aims to evaluate the safety profile and treatment effect after one dose of ELC-301. It

The exercise period for warrants of series TO3 begins today

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Today, on February 9, 2024, the subscription period begins for the warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The subscription period runs until February 23, 2024.Summarized

ClimateView and AFRY enter partnership for data-driven green transitions in cities

To support cities, municipalities and regions in accelerating their journey towards carbon neutrality, Swedish technology company ClimateView and global engineering and design company AFRY have entered a partnership with a joint offering, combining leading expertise from two disciplines.Cities are critical players in combating climate change, as they are hubs for innovation, economic activity and account for more than 70 percent of global CO2 emissions. Their dense populations and infrastructure offer a concentrated opportunity for both impactful policy changes and scalable sustainability

Fastighets AB Balder’s (publ) year-end report January-December 2023

· Profit from property management attributable to the parent company’s shareholders amounted to SEK 6,135m (6,139), corresponding to a decrease per share by 3% to SEK 5.32 (5.48).  · Long term net asset value amounted to SEK 85.06 per share (92.10).  · Rental income amounted to SEK 11,944m (10,521).  · Profit after tax attributable to the parent company’s shareholders amounted to SEK -6,746m (10,175) corresponding to SEK -5.85 per share (9.09). Profit from property management for the year amounted to SEK 6,549m (6,659). Profit from property management attributable to the

Year-end Report 1 January – 31 December 2023: Continued growth and healthy profitability sum up an intensive year

Fourth quarter 2023 • Net sales SEK 464.1 million (499.3) • EBITDA SEK 44.1 million (37.9), adjusted for non-recurring items, SEK 33.2 million (40.6) • EBITDA margin 9.5 percent (7.6), adjusted for non-recurring items, 7.2 percent (7.6) • EBIT SEK 39.3 million (31.3), adjusted for non-recurring items, SEK 28.4 million (34.0) • EBIT margin 8.5 percent (6.2), adjusted for non-recurring items, SEK 6.1 percent (6.7) • Profit after financial items SEK 41.5 million (29.9) • Profit for the period SEK 33.7 million (25.1) • Basic earnings per share SEK 3.53 (2.64) •

Invitation to Exel Composites’ Q1-Q4 2023 financial results briefing on 16 February 2024

EXEL COMPOSITES PLC          INVESTOR NEWS          9 FEBRUARY 2024 at 9:00 EETExel Composites will publish its Financial Statement Release for January – December 2023 on Friday 16 February 2024 at approximately 9:00 EET. Investors, analysts and journalists are invited to participate in the financial results briefing at 12:30 EET on the same day. The briefing will be hosted by President and CEO Paul Sohlberg and CFO Mikko Rummukainen.   The briefing will be organized online. To participate in the event, please register in advance by sending an email to investor@exelcomposites.com by

ABGSC – Q4 2023 Interim Report

Highlights: · Q4 revenues of NOK 545m (NOK 508m) · 2023 FY revenues of NOK 1,707m (NOK 1,704m) · 2023 diluted EPS of NOK 0.44 · Proposed cash dividend of NOK 0.50 per share · Solid and diversified pipeline for 2024 CEO comment: The macroeconomic landscape as we enter 2024 presents an array of challenges, as markets face risks stemming from geopolitical tensions, Europe's recession and China's slowdown. However, following a turbulent start to 2023, the financial markets surprised investors with a strong rally in stocks and bonds, driven by better economic growth,

Kemira Oyj: Notice to the Annual General Meeting

Kemira Oyj, Stock Exchange Release, February 9, 2024 at 9.00 am (EET)Kemira Oyj: Notice to the Annual General Meeting The shareholders of Kemira Oyj (“Kemira” or the “company”) are invited to the Annual General Meeting to be held on Wednesday, March 20, 2024 at 1.00 p.m. EET at Pikku-Finlandia (Little Finlandia), Karamzininranta 4, Helsinki, Finland. Reception of those registered for the meeting and distribution of voting tickets at the meeting venue will start at 12.00 p.m. EET.   The shareholders may also exercise their voting right by voting in advance. Instructions for advance

Change in Kemira Oyj’s Management Board: Harri Eronen appointed as Interim President, Pulp & Paper segment

Kemira Oyj, Stock Exchange Release, February 9, 2024 at 9.00 am  (EET)Change in Kemira Oyj’s Management Board: Harri Eronen appointed as Interim President, Pulp & Paper segment   Harri Eronen (1974) has been appointed as Interim President of Kemira’s Pulp & Paper segment and a member of Kemira’s management board as of February 12, 2024. The former President of the Pulp & Paper segment Antti Salminen will start as President & CEO of Kemira on February 12, 2024. Harri Eronen has had several prior leadership positions in Kemira since 2010, latest as Senior Vice President Commercial, Pulp

Year end report Image Systems January 1 - December 31 2023

Challenging 2023 ends with positive signals and increased order intake During a difficult 2023, in which the first three quarters were tough for the RemaSawco business unit, the Group has deliberately continued to invest in developing new products and improved customer service. We feel that confidence in the future, and thus a willingness to invest, increased among customers during the fourth quarter, and RemaSawco received several orders. This trend has continued in the beginning of 2024. At the same time, the Motion Analysis business unit operates in a growing market, which is expected

Transaction in Own Shares

    9 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |08/02/2024|+-----------------------------------------------------------

Olvi Group’s financial statements January–December 2023 - profitability improved

OLVI PLC                  Financial statements bulletin 9 February 2024 at 9.00 am Olvi Group’s financial statements January–December 2023 - profitability improved Net sales and profitability improved year-on-year as a result of strong sales volume growth in the first half of the year, implemented price increases and an extensive, constantly evolving product range that meets local needs. October–December 2023 · Sales volume decreased by 3.3% because of portfolio changes, campaign structures and pricing. · Net sales were EUR 134.7 (136.1) million, with a decrease of 1.1%,

Peab builds new swimming pool block in Partille

Peab has been commissioned to build a new swimming pool block in Partille Municipality. The customer is Partillebo and the contract is worth SEK 1.3 billion.The project consists of building a new swimming pool block containing a swimming pool facility, apartments, commercial space and parking garage in the borough Partille Port in central Partille. The swimming pool facility will have room for both training and relaxing and include an exercise pool, two multi-pools with height adjustable bottoms and a family pool with a waterslide. The facility will also have a separate relax section with

YIT’s Financial Statements Bulletin January-December 2023

YIT Corporation Stock Exchange Release 9 February 2024 at 09:00 a.m.YIT’s Financial Statements Bulletin January-December 2023   Operating cash flow after investments and financial position improved towards the end of the year.  2023 in brief  ·Order book was EUR 3,157 million (30 Sep 2023: 3,391). Order book decreased in Housing and remained stable in Business Premises and Infrastructure. At the end of the quarter, 74% of the order book was sold (30 Sep 2023: 75%).  ·Revenue decreased to EUR 2,163 million (2,403), increasing in Business Premises and decreasing in Housing

There are no items matching the current filter
There are no more items matching the current filter
Back to top